3Bastuji-Garin S, Rzany B, Stem RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme[J]. Arch Dermatol, 1993, 129(1): 92-96. 被引量：1
4Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study[J]. J Am Acad Dermatol, 2008, 58(1): 33-40. 被引量：1
5Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. 被引量：1
6Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case- control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68. 被引量：1
7Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis[J]. N Engl J Med, 1995, 333(24): 1600-1607. 被引量：1
8Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marked drugs. The EuroSCAR-study[J]. J Invest Dermatol, 2008, 128(1): 35-44. 被引量：1
9Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis[J]. J Am Acad Dermatol, 2013, 69(2): 173. 被引量：1
10Roujeau JC. Immune mechanisms in drug allergy[J]. Allergol Int, 2006, 55(1): 27-33. 被引量：1
